15.02.2017
Medios AG DE000A1MMCC8
DGAP-News: Medios AG continues dynamic growth in fiscal year 2016
DGAP-News: Medios AG / Key word(s): Preliminary Results
Medios AG continues dynamic growth in fiscal year 2016
15.02.2017 / 11:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Medios AG continues dynamic growth in fiscal year 2016
- Exceeded sales forecasts
- Strong growth thanks to heavy demand for personalized medicine
Berlin, February 15, 2017 - Medios AG, an expert pharmaceutical partner and
solution provider in the Specialty Pharma segment, experienced significant
growth in fiscal year 2016 thanks to strong demand for personalized
medicine. According to provisional consolidated calculations (pro forma,
IFRS), the corporation's sales revenue rose by 78% to EUR 160.5 million
compared to the prior year (PY EUR 90.1 million). This was higher than
market expectations.
The operating result (EBIT) made disproportionate gains of 100.4% to EUR
5.67 million (PY EUR 2.83 million), thus improving profitability: The EBIT
margin rose to 3.53 % (PY 3.14%).
"Fiscal year 2016 was outstanding for Medios. With a significant increase
in sales, we exceeded market expectations. As a result, we were able to
more than double our operating result. This enormous growth shows that
demand for personalized medicine is rising at a rapid pace. As a partner
for individual patient supply, we benefit from this development. Thanks to
our subsidiaries, Medios Pharma and Medios Manufaktur, we can cover two key
elements of the value-added chain. This puts us in an optimal position to
reach our goal of becoming the leading provider of Specialty Pharma
Solutions in Germany," says Matthias Gärtner, board member of Medios AG.
Both business divisions of Medios AG have contributed to the growth in both
sales and result: The subsidiary Medios Pharma GmbH, which operates as a
specialized wholesaler nationwide supplying pharmacies with drugs in such
areas as oncology, autoimmunology, and infectious diseases, generated sales
of EUR 127.5 million (PY EUR 58.2 million) and an EBIT of EUR 3.92 million
(PY EUR 1.06 million) in fiscal year 2016 according to IFRS. The subsidiary
Medios Manufaktur GmbH, which produces individual drugs for patients on
behalf of pharmacies, generated sales of EUR 43.5 million (PY EUR 35.3
million) and an EBIT of EUR 2.34 million (PY EUR 2 million) in fiscal year
2016 according to IFRS.
In addition to successful operations in fiscal year 2016, a high point was
the
economical re-formation of Medios AG as a result of contributing the two
subsidiaries. Medios AG also had an IPO on the regulated market of the
Frankfurt Stock Exchange (General Standard) through what is referred to as
a reverse IPO in addition to the successful placement of a cash capital
increase of EUR 19.3 million.
In early 2017, Medios AG announced the formation of a new subsidiary.
Medios Digital GmbH will take on all software development activities of
Medios AG and all other group companies in the future. It will provide
development, consulting, and operational services in the field of
information and system technology - with a focus on software development,
software maintenance and software support. The goal of Medios is broad
digitalization of the Specialty Pharma commercial business.
The 2016 Annual Report, including a forecast for fiscal year 2017, will be
published in April 2017.
About Medios AG
Medios AG, along with its subsidiaries Medios Pharma GmbH and Medios
Manufaktur GmbH, has positioned itself in the specialty pharma segment as
the go-to source for expertise and solutions. It brings together individual
market players in a network of cooperating partners. Our objective is to
ensure that patients have optimum access to pharmaceutical drugs and to
offer integrated solutions along the value-added chain to partners and
customers. Specialty pharmaceutical drugs are medications for patients with
rare and/or chronic illnesses (for example, certain cancer, autoimmune
diseases, and infectious diseases) that require lengthy and expensive
customised treatment.
Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Herrengraben 1
20459 Hamburg
Phone: +49 40 60918618
Fax: +49 40 60918660
E-mail: [email protected]
www.kirchhoff.de
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the forward-
looking statements contained in this notification.
---------------------------------------------------------------------------
15.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: 030 / 8321 8377
E-mail: [email protected]
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of News DGAP News Service
---------------------------------------------------------------------------
544721 15.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Medios AG ISIN: DE000A1MMCC8 können Sie bei EQS abrufen
Gesundheit , A1MMCC , ILM1 , XETR:ILM1